AMENDMENTS TO THE CLAIMS

- 1-7 (Canceled)
- 8. (Currently Amended) A method for treating a disease condition or deficiency through gene delivery of nucleic acid delivery to target cells of a subject comprising the step of administering a conjugating agent-nucleic acid complex where the conjugating agent comprises A-R₁-Q-Z, where A is a hydrophilic moiety that illustratively includes C₀-C₄ alkyl-hydroxy, -substituted amino, -quaternary amino, -sulfonate, -phosphonate, -carboxylate or a target ligand; where A-R1 R₁ is a cholesterol derivative; a C₈-C₂₄ alkyl; C₈-C₂₄ heteroatom substituted alkyl wherein the heteroatom is O, N, or S; or a bile acid; where Q is a sulfur, a secondary amine or oxygen having a nonessential N terminal amino-acid region nitrogen, or oxygen; and Z is a polyionic peptide.
- 9. (Previously Presented) The method of claim 8, wherein said administration is oral.
- 10. (Previously Presented) The method of claim 8, wherein nucleic acid of said complex is expressed as a protein in said target cells.
- 11. (Previously Presented) The method of claim 10 wherein said protein is secreted from said target cells.

- 12. (Previously Presented) The method of claim 10 wherein said protein is of a class selected from the group consisting of: proteases, pituitary hormones, protease inhibitors, growth factors, cytokines, somatomedians, chemokines, immunoglobulins, gonadotrophins, interleukins, chemotactins, interferons, and lipid-binding proteins.
- 13. (Currently Amended) The method of claim 8 wherein said nucleic acid of said complex is selected from the group consisting of: DNA, RNA, mRNA, miRNA, ribozyme, RNAse, and antisense sequences.
- 14. (Previously Presented) The method of claim 8 wherein said complex is administered as part of a pharmaceutical composition.
- 15. (Previously Presented) The method of claim 14 wherein said pharmaceutical composition comprises an active therapeutic compound.
- 16. (Currently Amended) The method of claim 15 wherein said therapeutic agent compound is selected from the group consisting of: an antibiotic, a gamma or beta radiation emitting species, an anti-inflammatory, an antitumoral, an antiviral, an antibody, a hormone, an enzyme, antigenic peptide and antigenic protein.
- 17. (Currently Amended) The method of claim 8 wherein A R₁ \underline{R}_1 is a cholesterol derivative.

- 18. (Currently Amended) The method of claim 17 8 wherein said A is a hydrophilic moiety.
- 19. (Previously Presented) The method of claim 8, wherein said target cells are gastrointestinal cells.
- 20. (Currently Amended) A gene nucleic acid delivery composition comprising a conjugating agent-nucleic acid complex having the formula:

$$A-R_1-Q-Y-Z$$

where A—R1 $\underline{R_1}$ is a cholesterol derivative; a C_8 - C_{24} alkyl; C_8 - C_{24} heteroatom substituted alkyl wherein the heteroatom is O, N or S; or a bile acid; where A is a hydrophilic moiety [[A]] that illustratively includes C_0 - C_4 alkyl-hydroxy, -substituted amino, -quaternary amino, -sulfonate, -phosphonate, and -carboxylate and or a target ligand; where Q is sulfur, nitrogen, or oxygen; where Y is a linker peptide having a negative, neutral, or positive charge; and where Z is a polyionic peptide.

- 21. (Previously Presented) The composition of claim 20 wherein said cholesterol derivative is selected from the group consisting of: cholestanol, coprostanol, cholic acid, glycocholic acid, chenodeoxycholic acid, desoxycholic acid, glycochenodeoxycholic acid, taurocholic acid, and taurochenodeoxycholic acid.
- 22. (Previously Presented) The composition of claim 20 wherein said cholesterol derivative is a cholic acid or a deoxycholic acid.

Serial No. 10/706,738 Reply to Office Action of April 17, 2006

- 23. (Currently Amended) The composition of claim 20 wherein said A derivative is hydroxyl C₀-C₄ alkyl-hydroxy.
- 24. (Currently Amended) The composition of claim 20 wherein said Q derivative is oxygen.
 - 25. (Canceled)
 - 26. (Previously Presented) The composition of claim 20 wherein Z is polycationic.
- 27. (Previously Presented) The composition of claim 26 wherein Z contains at least six residues.
 - 28. (Canceled)
 - 29. (Canceled)
- 30. (Currently Amended) A commercial package comprising a composition of Formula-I A-R₁-Q-Z according to claim 8 as an active ingredient together with instructions for the use thereof as a gene nucleic acid delivery agent to a subject.